Compare Quest Diagnostics Inc (DGX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Quest Diagnostics Inc trades at $237.85 (market cap $26.21B), while Consumer Staples Select Sector SPDR Fund trades at $84.94. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while Consumer Staples Select Sector SPDR Fund pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| DGX | XLP | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | — |
52-Week High | $238.50 | $90.00 |
52-Week Low | $173.49 | $75.61 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
XLP, the Consumer Staples Select Sector SPDR ETF, trades at $84.585, down 0.43% today. Technical indicators show a neutral overall signal with bullish moving averages, while oscillators remain neutral. The ETF's 2.6% dividend yield provides income appeal, with a dividend scheduled for payment on June 24, 2026. Recent news highlights consumer staples as a defensive play amid market rotation, with Coca-Cola's strong Q2 2026 earnings underscoring sector resilience (ETF Trends, July 29, 2026).
Outlook remains positive given 100% analyst buy ratings and defensive positioning during economic uncertainty. Key risks include sector concentration and sensitivity to consumer spending shifts. The ETF's stability and income generation support a favorable risk-reward profile for conservative investors seeking exposure to essential consumer goods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
